http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 16:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+21++Filed+by%3A+IMRAN+MIR+A/26808138.html si-local-file:///var/storage/secattach/20260723/26808138.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+21++Filed+by%3A+IMRAN+MIR+A/26808138.html Thu, 23 Jul 2026 16:10:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+21++Filed+by%3A+IMRAN+MIR+A/26808138.html si-local-file:///var/storage/secattach/20260723/26808138.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+21++Filed+by%3A+IMRAN+MIR+A/26808138.html Thu, 23 Jul 2026 16:10:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Mar+27++Filed+by%3A+Javadi+Alireza/26796801.html si-local-file:///var/storage/secattach/20260721/26796801.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Mar+27++Filed+by%3A+Javadi+Alireza/26796801.html Tue, 21 Jul 2026 19:24:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Mar+27++Filed+by%3A+Javadi+Alireza/26796801.html si-local-file:///var/storage/secattach/20260721/26796801.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Mar+27++Filed+by%3A+Javadi+Alireza/26796801.html Tue, 21 Jul 2026 19:24:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+17++Filed+by%3A+Imran+Talat/26796749.html si-local-file:///var/storage/secattach/20260721/26796749.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+17++Filed+by%3A+Imran+Talat/26796749.html Tue, 21 Jul 2026 18:29:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+17++Filed+by%3A+Imran+Talat/26796749.html si-local-file:///var/storage/secattach/20260721/26796749.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+17++Filed+by%3A+Imran+Talat/26796749.html Tue, 21 Jul 2026 18:29:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Dec+27++Filed+by%3A+Imran+Talat/26796742.html si-local-file:///var/storage/secattach/20260721/26796742.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Dec+27++Filed+by%3A+Imran+Talat/26796742.html Tue, 21 Jul 2026 18:25:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Dec+27++Filed+by%3A+Imran+Talat/26796742.html si-local-file:///var/storage/secattach/20260721/26796742.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Dec+27++Filed+by%3A+Imran+Talat/26796742.html Tue, 21 Jul 2026 18:25:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+17++Filed+by%3A+Maestas+Nicholas/26796290.html si-local-file:///var/storage/secattach/20260721/26796290.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+17++Filed+by%3A+Maestas+Nicholas/26796290.html Tue, 21 Jul 2026 16:51:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+17++Filed+by%3A+Maestas+Nicholas/26796290.html si-local-file:///var/storage/secattach/20260721/26796290.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Rani+Therapeutics+Holdin++For%3A+Jul+17++Filed+by%3A+Maestas+Nicholas/26796290.html Tue, 21 Jul 2026 16:51:00 -0400 O.52433366 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html <p>SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.</p> <p>The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html Mon, 20 Jul 2026 16:05:00 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html <p>SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.</p> <p>The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html Mon, 20 Jul 2026 16:05:00 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html <p>SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.</p> <p>The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html Mon, 20 Jul 2026 16:05:00 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html <p>SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.</p> <p>The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html Mon, 20 Jul 2026 16:05:00 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html <p>SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.</p> <p>The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html Mon, 20 Jul 2026 16:05:00 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html <p>SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.</p> <p>The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html Mon, 20 Jul 2026 16:05:00 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html <p>SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.</p> <p>The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html Mon, 20 Jul 2026 16:05:00 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html <p>SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.</p> <p>The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26789696.html Mon, 20 Jul 2026 16:05:00 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Rani+Therapeutics+Holdin+++++++++++++/26774921.html si-local-file:///var/storage/secattach/20260715/26774921.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Rani+Therapeutics+Holdin+++++++++++++/26774921.html Wed, 15 Jul 2026 17:10:00 -0400 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Rani+Therapeutics+Holdin+++++++++++++/26774921.html si-local-file:///var/storage/secattach/20260715/26774921.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Rani+Therapeutics+Holdin+++++++++++++/26774921.html Wed, 15 Jul 2026 17:10:00 -0400 O.52433366 RANI http://www.streetinsider.com/FDA/Rani+Therapeutics+oral+obesity+drug+tops+subcutaneous+exposure+in+Phase+1a/26771180.html <p>Rani Therapeutics Holdings (Nasdaq: RANI) reported initial Phase 1a data for RT-114, an oral capsule delivering PG-102, a GLP-1/GLP-2 dual agonist developed in collaboration with ProGen Co., Ltd. for the treatment of obesity.</p> <p>In the single-dose, open-label study, 30 healthy volunteers received a 12 mg dose of PG-102 either orally via the RaniPill Capsule or by subcutaneous injection. Oral RT-114 achieved systemic exposure greater than 150% relative to the matched subcutaneous dose. Elimination half-life was similar between the two groups, at 5.6 days for oral RT-114 and 5.3 days for subcutaneous PG-102.</p> <p>No serious adverse events were reported in either arm, and http://www.streetinsider.com/FDA/Rani+Therapeutics+oral+obesity+drug+tops+subcutaneous+exposure+in+Phase+1a/26771180.html Wed, 15 Jul 2026 08:00:57 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/FDA/Rani+Therapeutics+oral+obesity+drug+tops+subcutaneous+exposure+in+Phase+1a/26771180.html <p>Rani Therapeutics Holdings (Nasdaq: RANI) reported initial Phase 1a data for RT-114, an oral capsule delivering PG-102, a GLP-1/GLP-2 dual agonist developed in collaboration with ProGen Co., Ltd. for the treatment of obesity.</p> <p>In the single-dose, open-label study, 30 healthy volunteers received a 12 mg dose of PG-102 either orally via the RaniPill Capsule or by subcutaneous injection. Oral RT-114 achieved systemic exposure greater than 150% relative to the matched subcutaneous dose. Elimination half-life was similar between the two groups, at 5.6 days for oral RT-114 and 5.3 days for subcutaneous PG-102.</p> <p>No serious adverse events were reported in either arm, and http://www.streetinsider.com/FDA/Rani+Therapeutics+oral+obesity+drug+tops+subcutaneous+exposure+in+Phase+1a/26771180.html Wed, 15 Jul 2026 08:00:57 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/FDA/Rani+Therapeutics+oral+obesity+drug+tops+subcutaneous+exposure+in+Phase+1a/26771180.html <p>Rani Therapeutics Holdings (Nasdaq: RANI) reported initial Phase 1a data for RT-114, an oral capsule delivering PG-102, a GLP-1/GLP-2 dual agonist developed in collaboration with ProGen Co., Ltd. for the treatment of obesity.</p> <p>In the single-dose, open-label study, 30 healthy volunteers received a 12 mg dose of PG-102 either orally via the RaniPill Capsule or by subcutaneous injection. Oral RT-114 achieved systemic exposure greater than 150% relative to the matched subcutaneous dose. Elimination half-life was similar between the two groups, at 5.6 days for oral RT-114 and 5.3 days for subcutaneous PG-102.</p> <p>No serious adverse events were reported in either arm, and http://www.streetinsider.com/FDA/Rani+Therapeutics+oral+obesity+drug+tops+subcutaneous+exposure+in+Phase+1a/26771180.html Wed, 15 Jul 2026 08:00:57 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/FDA/Rani+Therapeutics+oral+obesity+drug+tops+subcutaneous+exposure+in+Phase+1a/26771180.html <p>Rani Therapeutics Holdings (Nasdaq: RANI) reported initial Phase 1a data for RT-114, an oral capsule delivering PG-102, a GLP-1/GLP-2 dual agonist developed in collaboration with ProGen Co., Ltd. for the treatment of obesity.</p> <p>In the single-dose, open-label study, 30 healthy volunteers received a 12 mg dose of PG-102 either orally via the RaniPill Capsule or by subcutaneous injection. Oral RT-114 achieved systemic exposure greater than 150% relative to the matched subcutaneous dose. Elimination half-life was similar between the two groups, at 5.6 days for oral RT-114 and 5.3 days for subcutaneous PG-102.</p> <p>No serious adverse events were reported in either arm, and http://www.streetinsider.com/FDA/Rani+Therapeutics+oral+obesity+drug+tops+subcutaneous+exposure+in+Phase+1a/26771180.html Wed, 15 Jul 2026 08:00:57 -0400 A.60004869 O.16363956 O.52433366 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+Positive+Initial+Phase+1a+Data+for+RT-114+for+the+Treatment+of+Obesity%2C+with+Oral+Bioavailability+Exceeding+Matched+Subcutaneous+Dosing/26771106.html <ul type="disc"><li><em>RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102</em><br/><br/></li><li><em>No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeutics</em><br/><br/></li><li><em>Phase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity</em><br/><br/></li></ul> <p align="justify">SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported positive initial data from the ongoing http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+Positive+Initial+Phase+1a+Data+for+RT-114+for+the+Treatment+of+Obesity%2C+with+Oral+Bioavailability+Exceeding+Matched+Subcutaneous+Dosing/26771106.html Wed, 15 Jul 2026 08:00:00 -0400 A.60004869 O.16363956 O.52433366 RANI